Recently, the latest report released by the market research company Global Industry Analysis (GIA) predicts that the clinical development of new drugs will promote the rapid growth of the global biomarker market. It is estimated that by 2017, the market size will reach US$34 billion.
According to GIA, during this period, the compound annual growth rate (CAGR) of biomarkers in clinical drug development applications will reach 26.5%. However, GIA also stated that the "great" capital investment required for the discovery, development, and application of biomarkers, as well as the high cost of biomarker verification, will be "a major factor hindering market growth." Some analysts believe that these obstacles may "force some small organizations and contract research organizations to completely abandon the use of biomarkers."
The "Biomarker: Global Strategic Business Report" released by GIA states that the discovery of biomarkers is the most important part of the global market, and the application of biomarkers in clinical applications is also increasing. It is during the period when nearly 90% of drug candidates have failed in clinical trials, and the development of biomarkers is gaining momentum.
Of course, the importance of biomarkers is that the key issues are toxicity, absorption, and metabolism in new drug research. GIA believes that biomarkers are an important tool for prevention of "significant loss" in the early stages, and drug development can choose suitable biomarkers instead of clinical endpoints.
Some studies have pointed out that cancer is an area with a particularly high failure rate in drug development. Therefore, oncology drug development shares a major share of the global biomarker market, and GIA said that biomarkers are widely used in early diagnosis and prognostic analysis of disease characteristics, as well as providing effective therapeutic drugs.
In addition, the global market for biomarkers in the field of heart disease will also grow rapidly. It is expected that by 2017, the compound annual growth rate will reach 24%. According to GIA, one of the major growth points of biomarkers is the rapid prediction of patients with heart failure under steady state conditions. In addition, biomarkers can also assess the risk of acute coronary syndrome, stroke, and other cardiovascular events in the patient's home and primary care settings.
According to the report, the United States is the largest biomarker market in terms of geographic area. GIA pointed out that the main factor for the growth of biomarkers in the United States and North America is that biomarkers accelerate drug development by helping researchers identify and validate complex targets.
It is expected that in the next few years until 2017, the fastest-growing biomarker market will be the Asia-Pacific region, with a compound annual growth rate of 28%. GIA believes that the key factor in the growth of the biomarker market in this region is the growing information technology industry in the region.
Overall, the global recession did not have a significant negative impact on the biomarker market. Analysts commented: “The global biomarker market will continue to move forward and will continue to grow at a double-digit rate even during the recession. Recently, new companies have emerged in the market to provide advanced technologies in the fields of chemical genomics, bioinformatics, genomics, metabolomics, transcription, peptidomics, glycoproteomics, proteomics, and pharmacogenomics. Technology platform. The report predicts that advances in these scientific fields may further encourage biomarker research to increase sample selection and enhance detection levels, resulting in multiple biomarker platforms for diagnosis, preclinical research, clinical trials, and product commercialization Increase the utility of biomarkers.
According to GIA, during this period, the compound annual growth rate (CAGR) of biomarkers in clinical drug development applications will reach 26.5%. However, GIA also stated that the "great" capital investment required for the discovery, development, and application of biomarkers, as well as the high cost of biomarker verification, will be "a major factor hindering market growth." Some analysts believe that these obstacles may "force some small organizations and contract research organizations to completely abandon the use of biomarkers."
The "Biomarker: Global Strategic Business Report" released by GIA states that the discovery of biomarkers is the most important part of the global market, and the application of biomarkers in clinical applications is also increasing. It is during the period when nearly 90% of drug candidates have failed in clinical trials, and the development of biomarkers is gaining momentum.
Of course, the importance of biomarkers is that the key issues are toxicity, absorption, and metabolism in new drug research. GIA believes that biomarkers are an important tool for prevention of "significant loss" in the early stages, and drug development can choose suitable biomarkers instead of clinical endpoints.
Some studies have pointed out that cancer is an area with a particularly high failure rate in drug development. Therefore, oncology drug development shares a major share of the global biomarker market, and GIA said that biomarkers are widely used in early diagnosis and prognostic analysis of disease characteristics, as well as providing effective therapeutic drugs.
In addition, the global market for biomarkers in the field of heart disease will also grow rapidly. It is expected that by 2017, the compound annual growth rate will reach 24%. According to GIA, one of the major growth points of biomarkers is the rapid prediction of patients with heart failure under steady state conditions. In addition, biomarkers can also assess the risk of acute coronary syndrome, stroke, and other cardiovascular events in the patient's home and primary care settings.
According to the report, the United States is the largest biomarker market in terms of geographic area. GIA pointed out that the main factor for the growth of biomarkers in the United States and North America is that biomarkers accelerate drug development by helping researchers identify and validate complex targets.
It is expected that in the next few years until 2017, the fastest-growing biomarker market will be the Asia-Pacific region, with a compound annual growth rate of 28%. GIA believes that the key factor in the growth of the biomarker market in this region is the growing information technology industry in the region.
Overall, the global recession did not have a significant negative impact on the biomarker market. Analysts commented: “The global biomarker market will continue to move forward and will continue to grow at a double-digit rate even during the recession. Recently, new companies have emerged in the market to provide advanced technologies in the fields of chemical genomics, bioinformatics, genomics, metabolomics, transcription, peptidomics, glycoproteomics, proteomics, and pharmacogenomics. Technology platform. The report predicts that advances in these scientific fields may further encourage biomarker research to increase sample selection and enhance detection levels, resulting in multiple biomarker platforms for diagnosis, preclinical research, clinical trials, and product commercialization Increase the utility of biomarkers.
Fireproof Safe,Fire Proof Safe,Rifle Fireproof Safe,Fire Resistant Safe
Ningbo Reliance Security Technology CO.,Ltd , https://www.reliancesafes.com